ADPT03A
Total Payments
$19,750
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $19,750 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $19,750 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A FIRST-IN-PATIENT PHASE I/II CLINICAL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF GENOME-EDITED HEMATOPOIETIC STEM AND PROGENITOR CELLS IN SICKLE CELL DISEASE | Novartis Pharmaceuticals Corporation | $19,750 | 0 |
Top Doctors Receiving Payments for ADPT03A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $19,750 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $19,750
- Total Doctors 0
- Transactions 2
About ADPT03A
ADPT03A is a drug associated with $19,750 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $19,750 was paid across 2 transactions to 0 doctors.
The most common payment nature for ADPT03A is "Unspecified" ($19,750, 100.0% of total).
ADPT03A is associated with 1 research study, including "A FIRST-IN-PATIENT PHASE I/II CLINICAL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF GENOME-EDITED HEMATOPOIETIC STEM AND PROGENITOR CELLS IN SICKLE CELL DISEASE" ($19,750).